De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Ipca Laboratories Toekomstige groei

Future criteriumcontroles 4/6

Ipca Laboratories zal naar verwachting groeien in winst en omzet met respectievelijk 30.9% en 11.9% per jaar. De winst per aandeel zal naar verwachting groeien met 31.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 15% zijn.

Belangrijke informatie

30.9%

Groei van de winst

31.1%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	18.0%
Inkomstengroei	11.9%
Toekomstig rendement op eigen vermogen	15.0%
Dekking van analisten	Good
Laatst bijgewerkt	02 Oct 2024

Recente toekomstige groei-updates

Recent updates

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Sep 10

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Sep 20

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Aug 09

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Jun 08

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Mar 26

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Mar 13

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Feb 28

Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Feb 23

Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Feb 11

Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Jan 30

The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It

Jan 15

Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly

Dec 31

Don't Ignore The Fact That This Insider Just Sold Some Shares In Ipca Laboratories Limited (NSE:IPCALAB)

Dec 16

The Case For Ipca Laboratories Limited (NSE:IPCALAB): Could It Be A Nice Addition To Your Dividend Portfolio?

Dec 13

Winst- en omzetgroeiprognoses

NSEI:IPCALAB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	113,656	14,353	11,105	N/A	10
3/31/2026	102,573	11,793	8,968	N/A	17
3/31/2025	90,139	8,899	7,860	N/A	17
6/30/2024	82,133	5,768	N/A	N/A	N/A
3/31/2024	77,059	5,474	5,341	9,447	N/A
12/31/2023	71,875	5,643	N/A	N/A	N/A
9/30/2023	66,806	4,922	2,612	6,767	N/A
6/30/2023	62,500	4,911	N/A	N/A	N/A
3/31/2023	62,481	4,713	3,113	8,058	N/A
12/31/2022	60,225	5,250	N/A	N/A	N/A
9/30/2022	59,070	6,142	2,398	7,616	N/A
6/30/2022	58,505	7,205	N/A	N/A	N/A
3/31/2022	58,305	8,841	3,771	8,561	N/A
12/31/2021	56,561	9,152	N/A	N/A	N/A
9/30/2021	56,355	9,837	3,728	8,554	N/A
6/30/2021	54,521	10,005	N/A	N/A	N/A
3/31/2021	54,207	11,400	7,286	10,901	N/A
12/31/2020	53,802	10,647	N/A	N/A	N/A
9/30/2020	51,833	9,968	7,371	10,767	N/A
6/30/2020	51,061	9,228	N/A	N/A	N/A
3/31/2020	46,499	6,063	2,641	5,704	N/A
12/31/2019	44,563	6,189	N/A	N/A	N/A
9/30/2019	42,496	5,804	2,877	5,181	N/A
6/30/2019	39,777	5,059	N/A	N/A	N/A
3/31/2019	37,750	4,448	3,205	5,010	N/A
3/31/2018	32,852	2,394	N/A	3,411	N/A
3/31/2017	31,562	1,945	N/A	2,819	N/A
3/31/2016	28,671	931	N/A	7,087	N/A
3/31/2015	31,444	2,542	N/A	4,682	N/A
3/31/2014	32,818	4,785	N/A	5,223	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei IPCALAB ( 30.9% per jaar) ligt boven de spaarquote ( 6.7% ).

Winst versus markt: De winst van IPCALAB ( 30.9% per jaar) zal naar verwachting sneller groeien dan de Indian markt ( 17.3% per jaar).

Hoge groeiwinsten: De winst van IPCALAB zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van IPCALAB ( 11.9% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.1% per jaar).

Hoge groei-inkomsten: De omzet van IPCALAB ( 11.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen IPCALAB zal naar verwachting over 3 jaar laag zijn ( 15 %).

Ipca Laboratories Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 8.6% to ₹1,320

Price target increased by 9.1% to ₹1,097

Price target increased by 9.7% to ₹987

Price target decreased by 7.1% to ₹858

Consensus EPS estimates fall by 21%

Price target decreased to ₹1,067

Recent updates

Ipca Laboratories Limited Announces Cessation of Manisha Premnath as Independent Director and Member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee, Effective September 21, 2024

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Price target increased by 8.6% to ₹1,320

Ipca Laboratories Limited Approves Appointment of Vivek Shiralkar as an Independent Director

Upcoming dividend of ₹2.00 per share

Ipca Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Less than half of directors are independent

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Ipca Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Full year 2024 earnings released: EPS: ₹25.82 (vs ₹18.58 in FY 2023)

Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

Ipca Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director

Price target increased by 9.1% to ₹1,097

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Ipca Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

CFO, MD & Executive Director recently sold ₹22m worth of stock

Price target increased by 9.7% to ₹987

Upcoming dividend of ₹2.00 per share at 0.2% yield

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023

Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Ipca Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q4, 2023 Results on May 29, 2023

Price target decreased by 7.1% to ₹858

Investor sentiment deteriorates as stock falls 15%

Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Consensus EPS estimates fall by 21%

Third quarter 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million.

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on December 7, 2022

Ipca Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Insider recently sold ₹1.7m worth of stock

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Ipca Laboratories Limited Approves Interim Dividend as Final Dividend for Financial Year Ended 31St March, 2022

Now 20% undervalued

Ipca Laboratories Limited Announced Demise of Dev Parkash Yadava, Non-Executive and Independent Director

Ipca Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Now 20% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2022

Now 20% undervalued after recent price drop

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Now 20% undervalued after recent price drop

Price target decreased to ₹1,067

Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Full year 2022 earnings: EPS misses analyst expectations

Insufficient new directors

CFO, Joint MD & Executive Director recently sold ₹21m worth of stock

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Price target decreased to ₹1,177

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ipca Laboratories Limited to Report Q3, 2022 Results on Feb 14, 2022

Ipca Laboratories Limited (BSE:524494) made an offer to acquire additional 26% stake in Lyka Labs Limited (BSE:500259) from Mayank J Shah, Shruti M Shah, Prasham M Shah and others for approximately INR 970 million.